New World's Bond Coupon Delay Raises Three Questions
In the bond world, not calling a perpetual is bad. But not repaying coupon? That's way worse.
Hong Kong-based New World Development Co.'s decision to defer interest payments on four perpetual notes took investors by surprise. While this is by no means an action of default — a perpetual resembles an equity when business conditions get tough — it's nonetheless a highly unconventional move.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
JW Therapeutics Announces Approval of Relmacabtagene Autoleucel Injection (Carteyva®) for Marketing in Macao
SHANGHAI, June 4, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that its new drugapplication (NDA) for the CAR-T cell immunotherapy product Carteyva® (relma-cel, targeting CD19) was approved by the Macao Special Administrative Region Government's Drug Regulatory Authority. This marks the first overseas market access for the product after its approval in mainland China, as well as a significant breakthrough in JW Therapeutics' global strategy. The approval covers three major indications, including: Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy; Adult patients with refractory or relapsed within 24 months follicular lymphoma after two or more lines of systemic therapy; Adult patients with relapsed or refractory mantle cell lymphoma after second line or above systemic treatment, including treatment with Bruton tyrosine kinase JW Therapeutics' first commercial product, the marketing approval of Carteyva® in Macao will further expand its accessibility in hematological oncology. Mr. Min LiuChairman and CEO of JW Therapeutics"The approval of Carteyva® in Macao marks the official launch of JW Therapeutics' internationalization journey, demonstrating our technical strength and regulatory recognition in the field of cell therapy. As our first overseas market, Macao lays a solid foundation for our expansion into Asia-Pacific and global markets. In the future, we'll speed up regional commercialization and strengthen global R&D and manufacturing collaboration to offer hope to more patients." View original content: SOURCE JW Therapeutics Sign in to access your portfolio
Bloomberg
an hour ago
- Bloomberg
Elon Musk's AI Startup Set to Get Debt Backing From TPG
TPG Angelo Gordon is an anchor investor in a debt package for Elon Musk's artificial intelligence startup, xAI Corp., according to people with knowledge of the matter. The firm is investing in a loan that is part of a debt offering for xAI, which Morgan Stanley started pre-marketing in recent weeks, said the people, who asked not to be identified discussing private information.
Bloomberg
an hour ago
- Bloomberg
Downward path with crude
Soybeans, grains could be akin to 2018, before fall The overhang for soybean and grain prices may be similar to 1H18, which marked a peak until 2020. A sharp spike in futures open interest to a record has characterized 2025, like seven years ago. What's different is the big jump in production and exports from Brazil, particularly in soybeans. The graphic shows the oilseed at about $10.60 a bushel on May 27, not far from the same date in 2018, while corn, soybeans and wheat open interest have backed down from February records. Our take is that new-long enthusiasm may have a similar outcome. In 2019, soybeans bottomed at about $7.90 a bushel due to trade issues. Record soybean exports this year, at around 117 million metric tons from Brazil and Argentina, are about 50% higher than in 2018 and more than double that of the US. A lowprice cure may come near 2019's $8.92 average. Grains may follow falling crude oil in 2025 WTI crude oil's inability since April to stay above 2024's $65 a barrel low may have similar deflationary implications for the grains. Roughly unchanged in 2025 to May 27, the Bloomberg Grains Spot Subindex faces a supply overhang from South America, declining demand from China, falling crude prices and a significant increase in US plantings of the world's most important grain — corn. Decent demand from Mexico and a weakening dollar are minor factors compared with the potential for a Corn Belt drought to support prices. Our bias is with the low probability for a Corn Belt supply shock vs. the potential for another good production year, backed by the trend of superabundance in oil and liquid fuels continuing to pressure prices. Absent a drought, legislation to buttress biofuel demand or exports may help buoy the grains. Crude's deflation from inflation may trickle down Crude oil is in a deflationary cycle following an inflation spike, and if the pattern since 1990 is a guide, $40 a barrel is a likely low-price cure. Staying above 2024's nadir of $65 may be an initial sign of recovery. Rising supply excesses from the US and OPEC, along with declining demand from China, are top headwinds. However, it's the potential for the US stock market's downward reversion that might matter the most. Our graphic shows the stretched S&P 500 vs. MSCI World Ex-US index, which may keep reverting from last year's 2.6x peak. From 1969-2014, this ratio of US stocks vs. the world stayed below 1x. Declining oil prices vs. record-setting gold is a global recessionary trajectory and if US equity prices continue to retrace some of the past decade's outsized gains, deflation from the inflation may dominate. Unknowns expanding around downstream demand US crops are mostly planted and looking strong, while China's temporary pause on steep tariffs may improve chances that crop exports aren't severely reduced. Scrutiny of crop chemicals was largely tabled until 2026 in an initial report from the MAHA Commission (which emphasized the importance of US farms' success). Yet a focus on ultra-processed foods could foreshadow greater disruption to grain and oilseed markets. Downstream, the results of our GLP-1 survey are ominous for food demand, with many Americans eliminating an entire daily meal and portion sizes falling. A large volume of small refinery exemptions clouds biofuels, which await the EPA's new volume obligations. Biofuel tax credits are part of the 'big, beautiful bill' now in Congress. Yet detailed regulations remain months away.
